Digital Health Works Insights

Medical Device Commercialization Plan: From Buyer to First Revenue

A practical plan for turning product readiness into a repeatable healthcare buying path

A medical device commercialization plan is not a launch calendar.

It is not a list of conferences, collateral, sales calls, and distribution targets. Those things matter, but they only help if the plan answers the harder question:

What has to become true for a real buyer to purchase, implement, and renew this product?

Medical device companies often reach commercialization with strong product progress and weak buying clarity. The device may work. The software may be ready. The regulatory path may be clear. Clinicians may be interested. But the company still may not know who owns the budget, what evidence the buyer needs, which channel can create demand, or how the first pilot becomes the first invoice.

A useful commercialization plan makes those questions explicit.

Start with the first revenue event

The first revenue event should be defined before the team builds the rest of the plan.

That does not mean the first possible sale. It means the first sale that teaches the company something repeatable.

The plan should describe:

the target account type
the buyer and economic owner
the clinical or operational user
the budget source
the decision process
the minimum evidence package
the expected contract structure
the implementation work required after signature

"Sell to hospitals" is not a plan. "Win paid adoption with outpatient imaging centers that need a safer CIED MRI workflow and can make the decision through radiology leadership with cardiology support" is much closer.

The narrower definition helps the team decide what to build, what to say, which accounts to pursue, and which objections matter.

Map the buyer, payer, user, and blocker

Healthcare buying is rarely a single-person decision.

A medical device commercialization plan should separate the people who use the product from the people who approve, pay, review, implement, or block the purchase.

At minimum, the plan should map:

clinical champion
department or service-line owner
procurement lead
finance or budget owner
compliance, legal, or privacy reviewer
IT or integration owner
executive sponsor
end users and support stakeholders

Each stakeholder has a different question. Clinicians may ask whether the product improves care. Finance may ask whether the economics are defensible. Procurement may ask whether the vendor is safe to contract with. IT may ask whether implementation creates ongoing burden. Executives may ask whether the product supports a strategic priority.

If the plan speaks to only one stakeholder, the deal can stall even when the product is liked.

Build the economic case before pricing

Pricing should not be invented in isolation.

Before the company decides whether to charge per device, per patient, per site, per subscription, per procedure, or through a partner model, it needs to understand where value lands.

The commercialization plan should answer:

Who benefits economically if the product is adopted?
Does the product create revenue, avoid cost, reduce risk, improve throughput, or protect capacity?
Is there a reimbursement pathway or budget line that supports adoption?
Does the economic benefit land with the same stakeholder who pays?
What price can the buyer defend internally?

This is where many commercialization plans become too optimistic. A product can create clinical value and still be hard to buy if the budget owner does not capture the benefit.

The plan should make that tension visible early.

Make evidence match the buying decision

Evidence is not only a regulatory or scientific asset. It is a commercial asset.

The evidence plan should support the claims the company needs buyers to believe. If the claim is clinical improvement, the evidence must support clinical improvement. If the claim is operational efficiency, the evidence must measure workflow. If the claim is cost avoidance, the plan needs credible economic assumptions and, eventually, real-world validation.

A commercialization plan should define:

what claim the company can make now
what claim it needs to make next
what evidence is missing
who will trust that evidence
what evidence belongs in procurement materials
what evidence belongs in sales conversations

The goal is not to collect more data for its own sake. The goal is to reduce buying risk.

Design the procurement path

Procurement is not the end of commercialization. It is part of commercialization.

A medical device commercialization plan should identify the approval sequence and the documents needed to move through it. That may include value analysis committee materials, privacy and security responses, contracting requirements, implementation plans, training materials, support documentation, reimbursement assumptions, and budget-impact language.

The plan should also identify likely objections:

"We do not have budget for this category."
"This creates workflow burden."
"The clinical case is interesting, but the economics are unclear."
"IT cannot support another integration."
"We need a champion from another department."
"This should wait until next budget cycle."

If these objections are predictable, the plan should prepare for them before sales begins.

Choose the channel around the buying work

Channel strategy should match the product and market.

Some products need founder-led selling early because the market story is still forming. Some need direct sales because education and implementation are heavy. Some can use distributors or manufacturer's representatives once the product has clear positioning, pricing, training materials, and support boundaries.

The commercialization plan should define:

which channel is appropriate for the first market segment
whether partners can create demand or only fulfill demand
what sales materials the channel needs
what margin or incentive structure makes the channel pay attention
what technical or clinical support the company must still provide
when to build internal sales capacity

Using a distributor too early can hide weak positioning. Keeping sales founder-led too long can hide weak repeatability. The plan should define the handoff points.

Turn pilots into commercial phases

If pilots are part of the plan, they should have conversion logic.

A pilot should define the buyer, budget owner, success criteria, commercial terms after success, support model, decision date, and evidence outputs before the pilot starts.

The plan should answer:

Why is this pilot commercially useful?
What will it prove for the buyer?
What will it prove for the company?
What happens if it succeeds?
What contract or expansion path follows?

Without those answers, the pilot may create activity without revenue.

Use milestones that show commercial learning

Good commercialization milestones are not only activity metrics.

Useful milestones include:

buyer segment validated
budget owner confirmed
value claim tested with target accounts
procurement packet completed
pricing defended with real buyers
first channel partner enabled
first paid pilot converted
first reference account created
implementation playbook reused

These milestones show whether commercialization risk is going down.

The plan should become more specific over time

A medical device commercialization plan is not meant to be perfect on day one. It should become more specific as the market responds.

The first buyer conversations should improve the value proposition. Procurement objections should improve the readiness packet. Implementation lessons should improve qualification. Partner conversations should improve channel strategy. Pricing feedback should improve the economic case.

The plan is useful when it creates this learning loop.

Practical takeaway

A medical device commercialization plan should connect product promise to a buying system.

That means defining the first revenue event, mapping stakeholders, building the economic case, matching evidence to buyer decisions, preparing for procurement, choosing the right channel, and designing pilots that can become contracts.

Commercialization starts working when the plan stops asking, "How do we launch?" and starts asking, "How does this become a purchase?"

Read this article on Digital Health Works